Syed Obaidur Rahman

Syed Obaidur Rahman

Auto-generated profile, based on publicly available information

Syed Obaidur Rahman

Pharmaceutical Medicine, Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi-110062,India

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
SRSyed Obaidur Rahman
Syed Obaidur Rahman
BPBibhu Panda
Bibhu Panda
SPSuhel Parvez
Suhel Parvez
MKMadhu Kaundal
Madhu Kaundal
SHSalman Hussain
Salman Hussain
ANAbul Kalam Najmi
Abul Kalam Najmi
With the constant failure of the clinical trials continuous exploration of a therapeutic target against Alzheimer's disease (AD) is the utmost need. Numerous studies have supported the hypothesis that central insulin resistance plays a significant role in AD. Serine phosphorylation of Insulin Receptor Substarte-1 (IRS-1) has been found to be a contributing factor in neuronal insulin resistance. Astaxanthin (ASX) is xanthophyll carotenoid which has previously demonstrated significant antidiabetic and neuroprotective actions. In the present study, AD was induced by i.c.v administration of Amyloid-β (1-42) peptides in Wistar rats. After 7 days of recovery, rats were treated with 0.5 mg/kg and 1 mg/kg of ASX orally for 28 days. Behavioral analysis was done in the last week of our experimental study. On the 36th day, rats were sacrificed and their hippocampus were separated from the whole brain, then homogenized and stored for biochemical estimations. ASX significantly and dose-dependently reversed the cognitive and memory impairment, assessed by Morris water maze test and Novel object Recognition test, Aβ (1-42) peptides infused Wistar rats. ASX also significantly attenuated soluble Aβ (1-42) level, IRS-S307 activity, GSK-3β activity, TNF-α level, AChE level, nitrite level and oxidative stress in the hippocampus. Histopathological evaluation, done through H&E and Congo red staining, also demonstrated neuroprotective and anti-amyloidogenic effects of ASX in hippocampus. Our study concludes preventive action of Astaxanthin against hippocampal insulin resistance and Alzheimer's disease complications, supporting potential role of hippocampal insulin resistance targeting against AD.

1 April 2018 in Neuroscience Letters
Verified
Journal Article
Closed access
SHSalman Hussain
Salman Hussain
Ambrish SinghAmbrish Singh
Ambrish Singh
SRSyed Obaidur Rahman
Syed Obaidur Rahman
AHAnwar Habib
Anwar Habib
ANAbul Kalam Najmi
Abul Kalam Najmi

23 July 2019 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
SHSalman Hussain
Salman Hussain
Ambrish SinghAmbrish Singh
Ambrish Singh
SZSaima Zameer
Saima Zameer
Mohammad Chand JamaliMohammad Chand Jamali
Mohammad Chand Jamali
HBHarveen Baxi
Harveen Baxi
ANAbul Kalam Najmi
Abul Kalam Najmi


27 March 2018 in Clinical and Experimental Hypertension
Verified
Journal Article
Closed access
Mohd ImranMohd Imran
Mohd Imran
QHQuamrul Hassan
Quamrul Hassan
SASayeed Akhtar
Sayeed Akhtar
ORObaid Rahman
Obaid Rahman
MAM. Akhtar
M. Akhtar
ANAbul Kalam Najmi
Abul Kalam Najmi
Background: Sacubitril (SAC), a neprilysin inhibitor prevent degradation of neprilysin and activate cGMP signaling pathways leading to rise in blood volume concurrent to blood pressure by means of vasoactive peptides, adrenomedullin, and bradykinin. Objective: The aim of this study was to evaluate the anti-ischemic effects of SAC through inhibiting neprilysin in isoproterenol (ISO) induced myocardial infarction (MI) in Wistar albino rats. ISO (85 mg/kg) was injected subcutaneously at the end of 14 days pre-treatment with SAC and valsartan (VAL). Result: Biochemical investigation revealed that SAC along with VAL significantly prevented the antioxidant enzymes (SOD, Catalase, GR, GPx, GST, and GSH) degradation and malondialdehyde (MDA) induced by ISO intoxication in Wistar rats. Along with this, cardiac biomarkers (LDH, CK-MB, ALT, AST, and ALP) were also significantly ameliorated by SACand VAL in ISO-treated rats. Concurrently, decreased infarction area (IA)and marked reduction in myofibril damage by SACand VAL further supported its protective benefits in MI. Conclusion: Taken together, the results suggest that inhibition of enzyme neprilysin alleviated the ISO induces myocardial damage mediated by its strong antioxidant potential.

1 April 2021 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
AIASHIF IQUBAL
ASHIF IQUBAL
SRSyed Obaidur Rahman
Syed Obaidur Rahman
MAMusheer Ahmed
Musheer Ahmed
PBPratichi Bansal
Pratichi Bansal
RHRafi Haider
Rafi Haider
SHSyed Ehtaishamul Haque
Syed Ehtaishamul Haque
Alzheimer’s disease is a common and most chronic neurological disorder (NDs) associated with cognitive dysfunction. Pathologically, Alzheimer’s disease (AD) is characterized by the presence of β-amyloid (Aβ) plaques, hyper-phosphorylated tau proteins, and neurofibrillary tangles, however, persistence oxidative-nitrative stress, endoplasmic reticulum stress, mitochondrial dysfunction, inflammatory cytokines, pro-apoptotic proteins along with altered neurotransmitters level are common etiological attributes in its pathogenesis. Rivastigmine, memantine, galantamine, and donepezil are FDA approved drugs for symptomatic management of AD, whereas tacrine has been withdrawn because of hepatotoxic profile. These approved drugs only exert symptomatic relief and exhibit poor patient compliance. In the current scenario, the number of published evidence shows the neuroprotective potential of naturally occurring bioactive molecules via their antioxidant, anti-inflammatory, antiapoptotic and neurotransmitter modulatory properties. Despite their potent therapeutic implications, concerns have arisen in context to their efficacy and probable clinical outcome. Thus, to overcome these glitches, many heterocyclic and cyclic hydrocarbon compounds inspired by natural sources have been synthesized and showed improved therapeutic activity. Computational studies (molecular docking) have been used to predict the binding affinity of these natural bioactive as well as synthetic compounds derived from natural sources for the acetylcholine esterase, α/β secretase Nuclear Factor kappa- light-chain-enhancer of activated B cells (NF-kB), Nuclear factor erythroid 2-related factor 2(Nrf2) and other neurological targets. Thus, in this review, we have discussed the molecular etiology of AD, focused on the pharmacotherapeutics of natural products, chemical and pharmacological aspects and multi-targeted designed ligands (MTDLs) of synthetic and semisynthetic molecules derived from the natural sources along with some important on-going clinical trials.